Results 11 to 20 of about 299,280 (207)

Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia [PDF]

Journal of the American Heart Association, 2019
Nandhini Sehar, Paul Barton Duell
exaly   +5 more sources

Asymptomatic Intracranial Artery Stenosis/Occlusion in Heterozygous Familial Hypercholesterolemia: Its Frequency and Implications for Cerebrovascular and Cardiovascular Events [PDF]

Journal of the American Heart Association
Background The atherogenic characteristics of heterozygous familial hypercholesterolemia (HeFH) increase the risk of premature atherosclerotic cardiovascular disease including not only coronary artery disease but ischemic stroke.
Teruo Noguchi, Yu Kataoka, Takahito Doi
exaly   +4 more sources

Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia [PDF]

New England Journal of Medicine, 2020
Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin-kexin type 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol levels. Its effects in pediatric patients with heterozygous familial hypercholesterolemia are not known.We conducted a 24-week, randomized, double-blind ...
Santos, Raul D., Ruzza, Andrea, Hovingh, G. Kees, Wiegman, Albert, Mach, François, Kurtz, Christopher E., Hamer, Andrew, Bridges, Ian, Bartuli, Andrea, Bergeron, Jean, Szamosi, Tamás, Santra, Saikat, Stefanutti, Claudia, Descamps, Olivier S., Greber-Platzer, Susanne, Luirink, Ilse, Kastelein, John J.P., Gaudet, Daniel, HAUSER-RCT Investigators, Sokal, Etienne   +19 more
openaire   +7 more sources

Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study [PDF]

Lipids in Health and Disease, 2022
Background Heterozygous familial hypercholesterolemia (HeFH) due to low-density lipoprotein receptor (LDLR) mutations predisposes patients to highly elevated levels of cholesterol, and patients are at increased risk of adverse cardiovascular events and ...
Kasper Aalbæk Kjærgaard, Sixten Harborg, Henrik Kjærulf Jensen, Signe Borgquist   +3 more
doaj   +2 more sources

Recent Advances on Familial Hypercholesterolemia in Children and Adolescents [PDF]

Biomedicines, 2022
Familial hypercholesterolemia is a common autosomal hereditary disorder characterized by elevated concentrations of low-density lipoprotein cholesterol and the development of premature atherosclerosis and cardiovascular disease.
Francesca Mainieri, Veronica Maria Tagi, Francesco Chiarelli   +2 more
doaj   +2 more sources

Awareness and knowledge of heterozygous familial hypercholesterolemia among Serbian pediatricians [PDF]

Frontiers in Pediatrics, 2023
ObjectivePublished reports describing awareness and knowledge of familial hypercholesterolemia (FH) among pediatricians are few and differ considerably across countries.
Ljiljana Bjelakovic, Lazar Stosic, Aleksandra Klisic, Marko Jovic, Sanja Stankovic, Aleksandra Stankovic, Sasa Pantelic, Danijela Zivkovic, Vladimir Vukovic, Vladimir Vukovic, Bojko Bjelakovic   +10 more
doaj   +2 more sources

Two Cases of Heterozygous Familial Hypercholesterolemia in Children Effectively Managed With Pitavastatin and Ezetimibe Combination Therapy [PDF]

Clinical Case Reports
Heterozygous familial hypercholesterolemia (HeFH) strongly predisposes individuals to atherosclerosis, including coronary artery disease, leading to death from cardiovascular diseases in > 60% of untreated cases.
Katsufumi Nishioka, Sonoko Kondo, Kanako Irie, Takeo Kondo, Takashi Iwase, Ryosuke Tani, Tomoko Inoue, Keiji Matsunaga, Tetsuo Minamino, Takashi Kusaka   +9 more
doaj   +2 more sources

Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside [PDF]

Drug Design, Development and Therapy, 2021
Anandita Agarwala,1 Renato Quispe,2 Anne C Goldberg,3 Erin D Michos2 1Division of Cardiology, Baylor Scott and White Health, Heart Hospital Baylor Plano, Plano, TX, USA; 2Ciccarone Center for the Prevention of Cardiovascular Disease, Division of ...
Agarwala A, Quispe R, Goldberg AC, Michos ED   +3 more
doaj   +2 more sources

Safety and Effectiveness of Low‐Density Lipoprotein Cholesterol–Lowering Therapy With Evolocumab for Familial Hypercholesterolemia/Hypercholesterolemia in Japan: A Real‐World, Postmarketing, Single‐Arm Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Evolocumab is the first monoclonal antibody against proprotein convertase subtilisin/kexin type 9 approved in Japan for familial hypercholesterolemia (FH) and hypercholesterolemia; however, data on its safety and effectiveness in the real ...
Koutaro Yokote, Junya Ako, Kazuo Kitagawa, Nobuhiro Osada, Feng Sheng, Masae Sonoda, Tamio Teramoto   +6 more
doaj   +2 more sources

Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia. [PDF]

PLoS ONE, 2016
The role of plasma cholesterol in impairing arterial function and elasticity remains unclear. We evaluated arterial stiffness, measured locally in the common carotid artery by high-resolution echo-tracking, and aortic stiffness, using carotid-femoral ...
Alexandra I Ershova, Alexey N Meshkov, Tatyana A Rozhkova, Maria V Kalinina, Alexander D Deev, Anatoliy N Rogoza, Tatyana V Balakhonova, Sergey A Boytsov   +7 more
doaj   +4 more sources